These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22507687)

  • 21. Fenofibrate increases the L-arginine:ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration.
    Dierkes J; Westphal S; Martens-Lobenhoffer J; Luley C; Bode-Böger SM
    Atherosclerosis; 2004 Apr; 173(2):239-44. PubMed ID: 15064097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of asymmetric dimethylarginine and homocysteine in microangiopathy-related cerebral damage.
    Notsu Y; Nabika T; Bokura H; Suyama Y; Kobayashi S; Yamaguchi S; Masuda J
    Am J Hypertens; 2009 Mar; 22(3):257-62. PubMed ID: 19057516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asymmetric dimethylarginine in adults with cystathionine β-synthase deficiency.
    Rocha MS; Teerlink T; Janssen MC; Kluijtmans LA; Smulders Y; Jakobs C; Tavares de Almeida I; Rivera I; Castro R; Blom HJ
    Atherosclerosis; 2012 Jun; 222(2):509-11. PubMed ID: 22484094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do cardiac risk factors affect the homocysteine and asymmetric dimethylarginine relationship in patients with coronary artery diseases?
    Işıklar OO; Barutcuoğlu B; Kabaroğlu C; Mutaf I; Özmen D; Bayındır O; Zoghi M; Uluer H
    Clin Biochem; 2012 Nov; 45(16-17):1325-30. PubMed ID: 22750146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum levels of homocysteine, asymmetric dimethylarginine and nitric oxide in patients with Parkinson's disease.
    Kirbas S; Kirbas A; Tufekci A; Cumhur Cure M; Cakmak S; Yazici T; Cure E
    Acta Clin Belg; 2016 Apr; 71(2):71-5. PubMed ID: 27075796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endothelin stimulates an endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, in experimental heart failure.
    Ohnishi M; Wada A; Tsutamoto T; Fujii M; Matsumoto T; Yamamoto T; Takayama T; Wang X; Kinoshita M
    Clin Sci (Lond); 2002 Aug; 103 Suppl 48():241S-244S. PubMed ID: 12193095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Asymmetric dimethylarginine and nitric oxide levels as signs of endothelial dysfunction in Behcet's disease.
    Sahin M; Arslan C; Naziroglu M; Tunc SE; Demirci M; Sutcu R; Yilmaz N
    Ann Clin Lab Sci; 2006; 36(4):449-54. PubMed ID: 17127734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.
    Nanayakkara PW; Kiefte-de Jong JC; ter Wee PM; Stehouwer CD; van Ittersum FJ; Olthof MR; Teerlink T; Twisk JW; van Guldener C; Smulders YM
    Am J Kidney Dis; 2009 Jan; 53(1):41-50. PubMed ID: 18786751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure.
    Nanayakkara PW; Teerlink T; Stehouwer CD; Allajar D; Spijkerman A; Schalkwijk C; ter Wee PM; van Guldener C
    Kidney Int; 2005 Nov; 68(5):2230-6. PubMed ID: 16221223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum homocysteine and asymmetric dimethylarginine levels in patients with premature ovarian failure: a prospective controlled study.
    Gulhan I; Bozkaya G; Bilgir F; Kebapcilar L; Bilgir O; Kavrut M; Dogan E
    Gynecol Endocrinol; 2011 Aug; 27(8):568-71. PubMed ID: 20626241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress.
    Suda O; Tsutsui M; Morishita T; Tasaki H; Ueno S; Nakata S; Tsujimoto T; Toyohira Y; Hayashida Y; Sasaguri Y; Ueta Y; Nakashima Y; Yanagihara N
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1682-8. PubMed ID: 15217805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes.
    Xiong Y; Lei M; Fu S; Fu Y
    Life Sci; 2005 May; 77(2):149-59. PubMed ID: 15862600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule.
    De Gennaro Colonna V; Bianchi M; Pascale V; Ferrario P; Morelli F; Pascale W; Tomasoni L; Turiel M
    Med Sci Monit; 2009 Apr; 15(4):RA91-101. PubMed ID: 19333216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
    Siroká R; Cibulka R; Rajdl D; Racek J
    Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension.
    Skoro-Sajer N; Mittermayer F; Panzenboeck A; Bonderman D; Sadushi R; Hitsch R; Jakowitsch J; Klepetko W; Kneussl MP; Wolzt M; Lang IM
    Am J Respir Crit Care Med; 2007 Dec; 176(11):1154-60. PubMed ID: 17872491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of homocysteine, asymmetric dimethylarginine, and nitric oxide with preeclampsia.
    Mao D; Che J; Li K; Han S; Yue Q; Zhu L; Zhang W; Li L
    Arch Gynecol Obstet; 2010 Oct; 282(4):371-5. PubMed ID: 19806356
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between S-adenosylmethionine, S-adenosylhomocysteine, asymmetric dimethylarginine, and endothelial function in healthy human subjects during experimental hyper- and hypohomocysteinemia.
    Doshi S; McDowell I; Goodfellow J; Stabler S; Boger R; Allen R; Newcombe R; Lewis M; Moat S
    Metabolism; 2005 Mar; 54(3):351-60. PubMed ID: 15736113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is asymmetric dimethylarginine responsible for the vascular events in patients under antiepileptic drug treatment?
    Oz O; Gökçil Z; Bek S; Cakir E; Odabaşi Z
    Epilepsy Res; 2009 Nov; 87(1):54-8. PubMed ID: 19713077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asymmetric dimethylarginine as a risk marker for early-onset ischemic stroke in Indian population.
    Mamatha SN; Nagaraja D; Philip M; Christopher R
    Clin Chim Acta; 2011 Jan; 412(1-2):139-42. PubMed ID: 20883678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease.
    Schnog JB; Teerlink T; van der Dijs FP; Duits AJ; Muskiet FA;
    Ann Hematol; 2005 May; 84(5):282-6. PubMed ID: 15599544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.